May 29, 2020 @ 6:00 am – May 30, 2020 @ 3:00 pm
This Event has passed
We regret to inform you that the EAP Spring Meeting that was scheduled to take place in Valletta, Malta from 29-30 May 2020 will be postponed to springtime 2021 due to the raging Covid-19 pandemic.
All participants who have registered and booked accommodation will be refunded through PayPal over the course of the next few days. If you have any questions or queries, feel free to contact the EAP Secretariat at secretariat@eapaediatrics.eu.
The EAP Spring Meeting that was scheduled to take place in Valletta, Malta from 29-30 May 2020 will be postponed to springtime 2021 due to the raging Covid-19 pandemic.
Registration Fees | Rate |
Full Participant (Incl. Social events)* | € 290 |
Participant (Incl. Friday Evening EAP Dinner) ** | € 260 |
Young EAP (Including Social events) | € 200 |
EAP Dinner for accompanying persons | € 70 |
Fees for full participant include: Meeting badge, participation in all sessions, printed material, invitation to
the EAP dinner on Friday, Saturday night networking evening, lunch (Friday & Saturday), coffee breaks.
Fees for participant meeting only include: Meeting badge, participation in all sessions, printed material,
lunch (Friday & Saturday), Friday night EAP Dinner and coffee breaks
Single Room | € 173 |
Double | € 194 |
Great Siege Road, Floriana FRN 1810, Malta
Valleta, 1810
Malta
+356 2125 0520
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.